Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | HM16390 |
| Synonyms | |
| Therapy Description |
HM16390 is a long-acting IL-2 analog, which potentially enhances antitumor immune response and inhibits tumor growth (Cancer Res (2024) 84 (7_Supplement): LB118). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| HM16390 | HM-16390|HM 16390 | HM16390 is a long-acting IL-2 analog, which potentially enhances antitumor immune response and inhibits tumor growth (Cancer Res (2024) 84 (7_Supplement): LB118). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06724016 | Phase I | HM16390 | Dose Escalation and Expansion Study of HM16390 in Advanced or Metastatic Solid Tumors | Recruiting | USA | 1 |